University of Wisconsin Carbone Cancer Center | Strategic Alliance Partners

March 07, 2024

Dr Kyriakopoulos sheds light on the potential synergy between masofaniten and enzalutamide when used in combination for patients with prostate cancer.

February 29, 2024

Kari Wisinski, MD, discusses treatment development and the current arsenal for patients with hormone receptor–positive, HER2-negative breast cancer.

January 30, 2024

Functional imaging information from 18F-FDG PET can complement data from anatomic imaging studies from CT and MRI to predict response to ICI therapy.

October 19, 2023

Drug development is a difficult and ever-changing process, with new agents being developed by industry and academic partners.

October 16, 2023

Kari Wisinski, MD, highlights the use of oral selective estrogen receptor degraders and CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative breast cancer, the growing role of antibody-drug conjugates across the breast cancer spectrum, and ongoing research taking place at Carbone Cancer Center.

September 29, 2023

Lubna Chaudhary, MD, MS, discusses the ongoing investigation and utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and compared this agent’s efficacy with that of trastuzumab emtansine.

September 18, 2023

Malinda West, MD, MS, discusses the use of adjuvant endocrine therapy in combination with CDK4/6 inhibitors in the treatment of patients with early-stage HER2-negative breast cancer.

September 06, 2023

State of the Science Summit - Breast Cancer: Chaired by Kari Wisinski, MD

August 10, 2023

Lisa Barroilhet, MD, discusses the role of PARP inhibitors in patients with ovarian cancer.

August 08, 2023

After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.

August 08, 2023

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

August 01, 2023

Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.

July 25, 2023

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.

July 25, 2023

Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.

July 18, 2023

Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.

July 18, 2023

Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.

July 11, 2023

Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.

July 11, 2023

A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.

July 04, 2023

Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.

July 04, 2023

Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.